New-age vaccine adjuvants, their development, and future perspective

Area of Science:

• Vaccinology and immunology
• Drug development and formulation

Background:

• Immunization is vital for preventing infectious diseases, but existing vaccines may offer inconsistent protection.
• Subunit vaccines are safe but often fail to elicit optimal immune responses.
• There is a critical need for improved vaccine strategies to combat emerging and persistent infectious threats.

Purpose of the Study:

• To review the necessity of novel vaccine adjuvants.
• To explore the characteristics and mechanisms of human-compatible adjuvants.
• To assess the current landscape and future directions of vaccine adjuvant development.

Main Methods:

• Literature review focusing on vaccinology, immunology, and adjuvant research.
• Analysis of existing data on vaccine efficacy and adjuvant performance.
• Synthesis of information on human-compatible adjuvants and their clinical development.

Main Results:

• Subunit vaccines require adjuvants to enhance immunogenicity.
• Novel adjuvants hold promise for improving vaccine efficacy and broadening protection.
• Limited human-compatible adjuvants are approved due to safety and toxicity concerns.

Conclusions:

• Adjuvants are essential for optimizing vaccine performance, especially for subunit vaccines.
• Further research into safe and effective human-compatible adjuvants is critical.
• Development of novel adjuvants is key to addressing challenges in vaccinology, including antigenic diversity and inconsistent protection.